| Target Validation Information | |||||
|---|---|---|---|---|---|
| TTD ID | T86885 | ||||
| Target Name | Beta-2-glycoprotein 1 (APOH) | ||||
| Type of Target |
Discontinued |
||||
| Action against Disease Model | LJP-1082 | Drug Info | LJP-1082 was conjugated to a defined, non-immunogenic organic platform to generate a tetravalent presentation of LJP-1082 for use as a toleragen. Tetravalent LJP-1082 induced a dose-dependent reduction in antibody levels in mice previously immunized and boosted with LJP-1082 coupled to the carrier keyhole limpet hemocyanin. These experiments support the technical feasibilityof a tolerance-based approach for reducing anti-beta2-GPI antibodies in vivo. | [1] | |
| References | |||||
| REF 1 | A chemically defined, toleragen-based approach for targeting anti-beta2-glycoprotein I antibodies. Lupus. 1998;7 Suppl 2:S166-9. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.